Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer hits enrollment goal
February 9th 2023"We are very pleased to have reached our recruitment target for the COBRA trial. The data generated thus far on the SAR-bisPSMA product is very encouraging and shows high uptake of the agent by prostate cancer cells,” said Neal Shore, MD.
Olaparib/abiraterone combo approved in European Union for mCRPC
December 21st 2022The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
FDA delays decision on olaparib/abiraterone combo for mCRPC
December 15th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
177Lu-PSMA-617 significantly improves rPFS in earlier mCRPC setting
December 6th 2022According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting.
Renal functional decline after radical nephrectomy strongly associated with age
December 2nd 2022“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Can theranostics improve outcomes in high-risk localized prostate cancer?
December 1st 2022Standard treatment is insufficient for some patients with high-risk localized prostate cancer, and the emerging field of theranostics provides a potential opportunity to improve outcomes, said Karen Elizabeth Hoffman, MD, MHSc, MPH.